WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
Coden USA: WJPRAP Impact Factor 8.453
Volume 15, Issue 3, 1477-1498. Review Article ISSN 2277–7105

SYNTHESIS, CHARACTERIZATION, AND BIOLOGICAL EVALUATION OF NOVEL BENZIMIDAZOLE DERIVATIVES AS POTENT ANTIFUNGAL AGENTS:

Miss. Tejasvinee Sahebrao Chaudhari[1*], Mr. Shaikh Habiburrahman[2], Dr. Mrunal K. Shirsat[3], Mr. Saeed Ahmad[4], Utkarsh Mahesh Patil[5]

[*1]Student, Department of Pharmaceutical Chemistry, Dr. Uttamrao Mahajan College of Pharmacy, Chalisgaon, Maharashtra, India.
[2]Assistant Professor, Department of Pharmaceutical Chemistry, Dr. Uttamrao Mahajan College of Pharmacy, Chalisgaon, Maharashtra, India.
[3]Principal: Deparment of pharmacognosy Dr. Uttamrao Mahajan College of Pharmacy, Chalisgaon, Maharashtra, Zindia.
[4]Assistant Professor, Department of Pharmaceutics, Dr.Uttamrao Mahajan College of Pharmacy Chalisgaon, Maharashtra India.
[5]Student of Pharmaceutical Chemistry, Dr.Uttamrao Mahajan College of Pharmacy Chalisgaon Maharashtra India.

Article Received on 05 Jan. 2026,
Article Revised on 25 Jan. 2026,
Article Published on 01 Feb. 2026,

https://doi.org/10.5281/zenodo.18479876

***Corresponding Author**
Miss. Tejasvinee Sahebrao Chaudhari
Student, Department of Pharmaceutical Chemistry, Dr. Uttamrao Mahajan College of Pharmacy, Chalisgaon, Maharashtra, India.

How to cite this Article: Miss. Tejasvinee Sahebrao Chaudhari[1]*, Mr. Shaikh Habiburrahman[2], Dr. Mrunal K. Shirsat[3], Mr. Saeed Ahmad[4], Utkarsh Mahesh Patil[5]. Synthesis, Characterization, and Biological Evaluation Of Novel Benzimidazole Derivatives As Potent Antifungal Agents:, 15(3), 1477–1498.

ABSTRACT

Benzimidazole derivatives have emerged as one of the most versatile heterocyclic scaffolds in medicinal chemistry due to their broad spectrum biological activities. Among these, antifungal activity has gained significant interest owing to rising incidences of fungal infections and increasing resistance to conventional antifungal drugs. This review comprehensively summarizes recent advances in the synthesis of benzimidazole derivatives, structural modifications aimed at enhancing antifungal potency, characterization techniques employed, and key biological evaluation results. Various synthetic strategies including traditional condensation, metal-catalyzed couplings, multicomponent reactions and green synthesis approaches are discussed. Structural features influencing antifungal activity, such as substituent effects, heterocyclic fusion, and hybridization with other pharmacophores, are critically analyzed. Characterization methods such as NMR, FTIR, Mass spectrometry, and elemental analysis are summarized. Finally,

insights into structure–activity relationships (SAR), modes of action, and future perspectives for benzimidazole antifungal agents are presented. This review aims to provide researchers in medicinal chemistry and pharmacology with a comprehensive resource for designing next-generation antifungal therapeutics based on benzimidazole frameworks.

KEYWORDS: Benzimidazole derivatives, antifungal agents, synthesis, characterization, structure–activity relationship, biological evaluation.

INTRODUCTION

Fungal infections have emerged as a serious and growing global health challenge, particularly among immunocompromised individuals, hospitalized patients, and patients receiving long-term immunosuppressive or broad-spectrum antibiotic therapy. Opportunistic fungal pathogens such as *Candida* species, *Aspergillus* species, and *Cryptococcus* species are responsible for a wide range of superficial, mucosal, and invasive systemic infections, often associated with high morbidity and mortality rates.[1,2] According to global epidemiological studies, invasive fungal infections account for more than 1.5 million deaths annually, emphasizing their significant clinical and economic burden.[3]

Despite the availability of several antifungal drug classes, including azoles, echinocandins, polyenes, and allylamines, current antifungal therapy suffers from several limitations. Azole antifungals, the most widely used class, are increasingly compromised by resistance mechanisms such as mutations in lanosterol 14α-demethylase (CYP51), overexpression of efflux pumps, and biofilm formation.[4,5] Polyene antifungals, particularly amphotericin B, exhibit broad-spectrum antifungal activity but are associated with severe nephrotoxicity and infusion-related adverse effects.[6] Echinocandins, although safer, show limited efficacy against certain fungal species and are ineffective against *Cryptococcus* infections.[7] These challenges underscore the urgent need for novel antifungal agents with improved safety profiles, broader spectrum of activity, and reduced resistance potential.

Heterocyclic compounds play a central role in medicinal chemistry due to their structural versatility and biological relevance. Among them, benzimidazole is recognized as a privileged heterocyclic scaffold owing to its fused benzene–imidazole ring system, which confers favorable electronic properties, planarity, and hydrogen bonding capability.[8] Benzimidazole derivatives have demonstrated a wide range of pharmacological activities, including antiviral, anticancer, antibacterial, antiparasitic, anti-inflammatory, and antifungal

effects.[9,10] The clinical success of benzimidazole-containing drugs such as thiabendazole, albendazole, and mebendazole highlights the therapeutic significance of this nucleus.[11]

The benzimidazole scaffold exhibits bioisosteric similarity to purine bases and naturally occurring nucleotides, allowing effective interaction with DNA, RNA, and enzyme active sites.[12] This structural resemblance enables strong binding interactions with fungal enzymes involved in critical biosynthetic pathways, including ergosterol biosynthesis and cell wall formation. Moreover, the benzimidazole ring offers multiple sites for substitution, particularly at the 2-, 5-, and 6-positions, facilitating extensive structural modification to optimize antifungal potency, selectivity, and pharmacokinetic behaviour.[13] Numerous studies have demonstrated that electron-withdrawing or heterocyclic substituents at these positions significantly enhance antifungal activity against *Candida* and *Aspergillus* species.[14]

In recent years, medicinal chemistry research has increasingly focused on the development of novel benzimidazole derivatives and hybrid molecules combining benzimidazole with other antifungal pharmacophores such as triazoles, thiazoles, oxadiazoles, and pyrimidines.[15,16]

These hybridization strategies aim to achieve synergistic antifungal effects, overcome resistance mechanisms, and improve target specificity. Advances in synthetic methodologies, including microwave-assisted synthesis, multicomponent reactions, and green chemistry approaches, have further accelerated the discovery of structurally diverse benzimidazole analogues.[17] Structural confirmation of these compounds is routinely achieved using modern spectroscopic and analytical techniques such as NMR spectroscopy, FTIR, mass spectrometry, elemental analysis, and X-ray crystallography.[18]

In this context, the present review provides a comprehensive overview of recent advances in the synthesis, characterization, and biological evaluation of novel benzimidazole derivatives as potent antifungal agents reported over the past decade. Special emphasis is placed on synthetic strategies, structure–activity relationship (SAR) analysis, antifungal screening methodologies, and mechanistic insights. By consolidating and critically analyzing existing literature, this review aims to support rational drug design and guide future research toward the development of next-generation antifungal agents based on the benzimidazole framework.

Benzimidazole: Structure and Biological Importance

Benzimidazole is a bicyclic heterocyclic compound formed by the fusion of a benzene ring with an imidazole nucleus. This fused ring system results in a planar and rigid structure, which is highly favorable for interaction with various biological macromolecules such as enzymes, receptors, and nucleic acids. The presence of two nitrogen atoms within the imidazole ring contributes to the basicity and hydrogen-bonding capability of the benzimidazole scaffold, making it an important pharmacophore in medicinal chemistry.[1,2]

The benzimidazole core is considered an electron-rich heterocycle, which provides multiple reactive sites suitable for chemical substitution. These electron-donating characteristics enhance its ability to participate in π–π stacking, hydrogen bonding, and coordination interactions with biological targets. Due to this structural versatility, benzimidazole derivatives exhibit a wide spectrum of biological activities, including antifungal, antibacterial, antiviral, anticancer, antiparasitic, and anti-inflammatory effects.[3] The ease of functionalization at different positions of the benzimidazole ring allows medicinal chemists to modulate physicochemical and pharmacological properties effectively.

Several clinically important antifungal and antiparasitic agents contain the benzimidazole nucleus or related structural motifs, highlighting the therapeutic potential of this scaffold. Drugs such as **thiabendazole**, **fenbendazole**, **albendazole**, and **mebendazole** are well-known benzimidazole derivatives that exert their biological effects primarily through inhibition of microtubule assembly and disruption of cellular metabolism.[4] Thiabendazole, in particular, has demonstrated significant antifungal activity against a range of pathogenic fungi, thereby validating benzimidazole as a promising lead structure for antifungal drug development.[5]

The biological activity of benzimidazole derivatives is strongly influenced by the nature and position of substituents on the core structure. Substitutions at the **2-position** are particularly critical, as this site directly affects lipophilicity, target binding affinity, and antifungal potency. Aromatic, heteroaromatic, or alkyl substituents at this position have been shown to enhance membrane permeability and enzyme inhibition.[6] Similarly, substitutions at the **5- and 6-positions** of the benzene ring significantly influence electronic distribution and biological selectivity. Electron-withdrawing groups such as nitro, halogens, and trifluoromethyl groups at these positions often enhance antifungal activity by improving binding interactions with fungal enzymes involved in ergosterol biosynthesis.[7]

Furthermore, heterocyclic fusion or hybridization of the benzimidazole nucleus with other biologically active moieties, such as triazoles, thiazoles, oxadiazoles, and pyrimidines, has emerged as an effective strategy to improve antifungal efficacy and overcome resistance. These hybrid molecules often exhibit synergistic effects, broader antifungal spectrum, and improved pharmacokinetic profiles compared to parent benzimidazole compounds.[8] Thus, the structural flexibility and proven biological relevance of the benzimidazole scaffold make it a valuable platform for the design and development of novel antifungal agents.



Figure 1: General Structure of Benzimidazole.

Synthetic Strategies for Benzimidazole Derivatives

The benzimidazole nucleus has attracted considerable attention in medicinal chemistry owing to its synthetic accessibility and structural versatility. Numerous synthetic methodologies have been developed to generate structurally diverse benzimidazole derivatives with improved antifungal activity. These strategies range from conventional condensation reactions to modern metal-catalyzed, multicomponent, green, and hybridization approaches. A detailed overview of these synthetic routes is discussed below.



Scheme 1: Classical Condensation Synthesis.

Classical Condensation Methods

The most widely employed and traditional method for the synthesis of benzimidazole derivatives involves the condensation of **o-phenylenediamine** with carboxylic acids, aldehydes, or their derivatives. Typically, this reaction proceeds through acid-catalyzed cyclization, resulting in the formation of the benzimidazole ring system. Commonly used acids include hydrochloric acid, acetic acid, polyphosphoric acid, or Lewis acids, while reactions are often conducted under reflux conditions.[18,19]

In the case of aldehydes, the reaction mechanism involves initial Schiff base formation between the aldehyde and one amino group of o-phenylenediamine, followed by intramolecular cyclization and oxidative aromatization. This approach is particularly useful for synthesizing **2-substituted benzimidazole derivatives**, which are known to play a crucial role in modulating antifungal activity. The method is favored due to its simplicity, availability of starting materials, relatively high yields, and ease of purification.[20]

Advantages of classical condensation methods include operational simplicity, cost-effectiveness, and suitability for large-scale synthesis. However, drawbacks such as longer reaction times, harsh acidic conditions, and limited functional group tolerance have encouraged the development of alternative synthetic strategies.



Scheme 2: Metal-Catalyzed Coupling (Suzuki / Buchwald).

Metal-Catalyzed Coupling Reactions

Metal-catalyzed cross-coupling reactions have emerged as powerful tools for the functionalization of the benzimidazole scaffold, enabling the formation of **C–C and C–N bonds** with high regioselectivity and efficiency. Palladium- and copper-catalyzed reactions are particularly popular for introducing aryl, heteroaryl, and alkyl substituents at various positions of the benzimidazole ring.[21]

Among these, **Suzuki–Miyaura coupling** is extensively used for synthesizing 2-aryl or 5-aryl benzimidazole derivatives by reacting halo-substituted benzimidazoles with aryl boronic acids in the presence of a Pd(0) catalyst and a suitable base. Similarly, **Buchwald–Hartwig amination** facilitates the introduction of amine or heterocyclic moieties via C–N bond formation, significantly expanding the chemical diversity of benzimidazole derivatives.[22,23]

These advanced coupling techniques offer high yields, excellent functional group tolerance, and structural complexity, making them highly suitable for medicinal chemistry programs aimed at optimizing antifungal potency and selectivity.

Multicomponent and Green Synthetic Approaches

In recent years, **multicomponent reactions (MCRs)** have gained prominence as efficient and environmentally friendly synthetic strategies for benzimidazole derivatives. These reactions involve the combination of three or more reactants in a single reaction vessel to form complex products in a one-pot manner. Typical MCRs include the reaction of o-phenylenediamine, aldehydes, and isocyanides to yield fused or substituted benzimidazole derivatives with high atom economy.[24]

Microwave-assisted synthesis has further enhanced these methods by significantly reducing reaction times, improving yields, and minimizing energy consumption. Microwave irradiation promotes uniform heating and accelerates cyclization reactions, making it a preferred technique for rapid synthesis.[25]

Additionally, green chemistry approaches employing **ionic liquids, recyclable catalysts, and nano-catalysts** have been explored to reduce solvent usage, waste generation, and environmental impact. These sustainable methodologies align with modern pharmaceutical research objectives while maintaining high synthetic efficiency.[26,27]

Hybrid Molecule Strategy

The hybrid molecule approach involves the conjugation of the benzimidazole nucleus with other biologically active antifungal pharmacophores to produce multifunctional compounds with enhanced therapeutic potential. Benzimidazole hybrids incorporating **triazoles, thiazoles, pyrimidines, oxadiazoles, and other heterocycles** have demonstrated superior antifungal activity compared to parent compounds.[28]



Scheme 3: Benzimidazole–Triazole Hybrid Synthesis.

Triazole–benzimidazole hybrids, for instance, are designed to target fungal ergosterol biosynthesis while simultaneously disrupting cellular integrity. Thiazole and pyrimidine conjugates have been reported to exhibit improved binding affinity, broader antifungal spectrum, and reduced resistance development. Such hybridization strategies are increasingly recognized as effective tools for next-generation antifungal drug discovery.[29,30]

Table 1: Representative Synthetic Routes and Key Reaction Conditions.

Entry	Reactants	Catalyst / Condition	Product Type	Yield (%)
1	1,2-Phenylenediamine + R-aldehyde	HCl, reflux	2-Substituted benzimidazole	70–85
2	2-Halo-benzimidazole + aryl boronic acid	Pd(0), base	2-Aryl benzimidazole	65–90
3	o-Phenylenediamine + aldehyde + isocyanide (MCR)	Microwave irradiation	Fused benzimidazole	60–80

Characterization Techniques

Accurate characterization of newly synthesized benzimidazole derivatives is a crucial step to confirm their chemical structure, purity, and suitability for biological evaluation. Modern analytical and spectroscopic techniques provide complementary information regarding functional groups, molecular framework, and three-dimensional geometry. The most commonly employed characterization techniques are discussed below.

Nuclear Magnetic Resonance (NMR) Spectroscopy

Nuclear Magnetic Resonance (NMR) spectroscopy is a fundamental technique for structural elucidation of organic molecules, including benzimidazole derivatives. Both ^1H and ^13C NMR spectra are routinely recorded to determine chemical shifts, multiplicity, coupling constants, and integration values. The ^1H NMR spectrum provides information on hydrogen environments, allowing assignment of protons attached to aromatic rings, heteroatoms, and substituents at positions 2, 5, or 6. The ^13C NMR spectrum helps confirm the carbon framework, including quaternary carbons, carbonyl groups, and substituted aromatic carbons.[31] Advanced two-dimensional NMR techniques, such as COSY, HSQC, and HMBC, are often employed to resolve complex spectra and establish connectivity in multi-substituted derivatives.[32]

Fourier Transform Infrared (FTIR) Spectroscopy

FTIR spectroscopy is widely used to identify functional groups present in benzimidazole derivatives. Characteristic absorption bands corresponding to N–H, C=N, C–C, C–N, and aromatic C–H stretching provide confirmation of successful cyclization and functionalization. For example, the benzimidazole N–H stretching typically appears in the range of 3100–3400 cm^{-1}, while C=N stretching is observed around 1600–1650 cm^{-1}.[33] FTIR also enables verification of substituents such as nitro, halogens, or carbonyl groups introduced during synthetic modifications.

Mass Spectrometry (MS)

Mass spectrometry is essential for determining the molecular weight, molecular formula, and fragmentation pattern of novel benzimidazole derivatives. Molecular ion peaks ([M]+) confirm the expected molecular mass, while fragmentation patterns provide insights into substituent positions and ring stability. High-resolution mass spectrometry (HRMS) is particularly useful for confirming elemental composition with high accuracy, which is critical for derivatives with multiple heteroatoms.[34,35]

Elemental Analysis

Elemental analysis is employed to determine the carbon (C), hydrogen (H), and nitrogen (N) content of benzimidazole compounds. This technique ensures that the synthesized derivatives are consistent with their proposed molecular formula and helps assess sample purity. Deviations from theoretical percentages may indicate incomplete reactions or the presence of residual solvents.[36]

X-ray Crystallography

Single-crystal X-ray diffraction is the most definitive method for confirming the three-dimensional structure of key benzimidazole derivatives. It provides precise information on bond lengths, bond angles, planarity, and stereochemistry, which is critical for understanding structure–activity relationships (SAR). X-ray crystallography is particularly valuable for derivatives with complex substitution patterns or fused heterocycles, enabling correlation between molecular geometry and antifungal activity.[37,38]

Figure 3: Key Spectotorotic and Crystaraptic Data for Benzimidazole Derivatives

A) Representative ¹H NMR Spectrum



B) Single-Crestal X-ray Crystoragtic Structure (ORTEP Plot)



Figure 3: Representative ¹" MR Spectrum and-X Cristal Structre of a Novel Benzimaible Derviative

Biological Evaluation

The antifungal potential of benzimidazole derivatives has been extensively investigated through in vitro and in vivo assays. Biological evaluation is critical for correlating chemical structure with antifungal efficacy, guiding structure–activity relationship (SAR) studies, and identifying lead compounds for further development.

Antifungal Assay Types

The most commonly employed in vitro assays for benzimidazole derivatives target clinically relevant pathogenic fungi such as *Candida albicans*, *Aspergillus niger*, and *Cryptococcus*

neoformans. These assays provide a quantitative measure of antifungal potency and facilitate comparison with standard antifungal drugs.

1. Broth Microdilution Method This method, recommended by the Clinical and Laboratory Standards Institute (CLSI), determines the minimum inhibitory concentration (MIC) of test compounds. MIC represents the lowest concentration that visibly inhibits fungal growth after a defined incubation period.[39]
2. Agar Well Diffusion Assay In this qualitative assay, compounds are introduced into wells on agar plates inoculated with fungal strains. The zone of inhibition around the wells indicates antifungal activity, providing a rapid screening tool for multiple derivatives.[40]
3. Time-Kill Kinetics Time-kill studies assess the rate and extent of fungicidal action over time. This method is particularly useful for evaluating hybrid molecules or derivatives with potential synergistic effects, providing insights into the mechanism of action.[41]

Representative Biological Data

The antifungal activity of selected benzimidazole derivatives against clinically relevant fungi is summarized in Table 2. The data highlight how structural modifications, such as substituents at position 2, 5, or hybridization with other pharmacophores, influence antifungal potency.

Table 2: Antifungal Activity of Selected Benzimidazole Derivatives.

Compound	Substitution	Organism	MIC (µg/mL)	Standard (Control)
A	2-Aryl	*C. albicans*	8	Fluconazole: 16
B	5-Nitro	*A. niger*	4	Ketoconazole: 8
C	Benzimidazole–Triazole Hybrid	*C. neoformans*	2	Amphotericin B: 1



Figure 4: Comparative Antifungal Activity (MIC in µg/mL) of Synthesized Benzimidazole Derivatives (A, B, C) against Standard Drugs.

Antiparasitic Activity of Benzimidazole Derivatives

Benzimidazole derivatives constitute one of the most successful classes of antiparasitic agents and have been extensively used in the treatment of helminthic and protozoal infections. Clinically approved benzimidazole drugs such as albendazole, mebendazole, thiabendazole, and flubendazole exert their antiparasitic action primarily by binding to β-tubulin, thereby inhibiting microtubule polymerization. This disruption impairs glucose uptake, intracellular transport, and cell division in parasites, ultimately leading to energy depletion and parasite death.

Structural modifications at the 2-position and substitutions on the benzimidazole phenyl ring (particularly at the 5- and 6-positions) have been reported to enhance antiparasitic potency and spectrum of activity. Lipophilic substituents improve membrane permeability, while electron-withdrawing groups increase binding affinity toward parasite tubulin. Recent studies have demonstrated that benzimidazole hybrids and prodrug approaches exhibit improved efficacy against resistant parasitic strains, highlighting the continued relevance of this scaffold in antiparasitic drug discovery.[35,44]

Anticancer Activity of Benzimidazole Derivatives

In recent years, benzimidazole derivatives have gained significant attention as promising anticancer agents due to their ability to interfere with multiple cellular targets involved in cancer progression. Several benzimidazole-based compounds have been reported to exhibit potent cytotoxic activity against a wide range of cancer cell lines, including breast, lung, colon, prostate, and leukemia cells.

The anticancer mechanism of benzimidazole derivatives is multifaceted and includes tubulin polymerization inhibition, induction of apoptosis via mitochondrial pathways, cell cycle arrest at G2/M phase, and inhibition of angiogenesis. Structural hybridization of benzimidazole with pharmacophores such as triazoles, quinazolines, and chalcones has resulted in compounds with enhanced selectivity and reduced toxicity. Substitutions at the 2-position and incorporation of electron-donating or heterocyclic moieties significantly influence anticancer potency. These findings suggest that benzimidazole serves as a versatile scaffold for the development of novel anticancer therapeutics.[40]

Key Findings

- Substituent Effects: Electron-withdrawing groups at position 5 (e.g., nitro, halogen) enhance antifungal potency by facilitating stronger interactions with fungal enzymes involved in ergosterol biosynthesis.[42]
- Hybrid Molecules: Benzimidazole–triazole conjugates show synergistic antifungal effects, often outperforming standard antifungals in MIC assays, suggesting additive or complementary mechanisms of action.[43]
- 2-Position Substitutions: Aromatic or heteroaromatic substituents at position 2 enhance lipophilicity, membrane permeability, and enzyme binding, improving overall antifungal activity.[44]
- Spectrum of Activity: Some derivatives demonstrate broad-spectrum activity across multiple fungal species, highlighting their potential as versatile antifungal agents.

These findings underline the importance of systematic SAR studies for optimizing benzimidazole derivatives as antifungal therapeutics.



Figure 5: SAR of Benzimidazole Antifungal Agents.

Structure–Activity Relationship (SAR) of Benzimidazole Derivatives

The structure–activity relationship (SAR) of benzimidazole derivatives provides crucial insights into how chemical modifications influence antifungal potency, selectivity, and spectrum of activity. Understanding SAR allows rational design of novel derivatives with optimized therapeutic profiles.

Substitutions at the 2-Position

The 2-position of the benzimidazole nucleus is particularly critical for antifungal activity. Introduction of aromatic, heteroaromatic, or alkyl substituents at this site enhances lipophilicity, facilitating better penetration through fungal cell membranes. This interaction is essential for compounds targeting membrane-bound enzymes or interfering with membrane integrity.[45] Studies have shown that 2-aryl or 2-heteroaryl benzimidazole derivatives demonstrate significantly lower MIC values against *Candida albicans* and *Aspergillus niger* compared to unsubstituted analogues.[46]

Electron-Withdrawing Substituents

Electron-withdrawing groups (EWGs) such as nitro (–NO2), trifluoromethyl (–CF3), and halogens at positions 5 or 6 of the benzimidazole scaffold substantially improve antifungal potency. These substituents enhance the compound's ability to interact with fungal enzymes involved in ergosterol biosynthesis, particularly lanosterol 14α-demethylase (CYP51). The increased binding affinity leads to effective inhibition of ergosterol formation, disrupting fungal membrane integrity and resulting in fungistatic or fungicidal effects.[47,48]

Heterocyclic Fusion

Fusing the benzimidazole nucleus with other heterocycles, such as triazoles, thiazoles, oxadiazoles, or pyrimidines, can significantly improve enzyme binding and antifungal efficacy. Heterocyclic fusion often enhances hydrogen bonding and π–π stacking interactions with the active site of CYP51 or other fungal targets, leading to improved selectivity and potency. These fused derivatives have been reported to exhibit lower MIC values and broader antifungal spectrum compared to non-fused analogues.[49]

Hybrid Molecule Strategy

The design of hybrid benzimidazole derivatives, combining multiple pharmacophores, is an effective approach to overcome drug resistance and expand antifungal activity. For instance, benzimidazole–triazole hybrids show synergistic activity by simultaneously targeting multiple fungal pathways. Hybrids often demonstrate improved pharmacokinetic properties, reduced toxicity, and broader spectrum against resistant fungal strains.[50,51] These findings underscore the importance of strategic molecular hybridization in the development of next-generation antifungal agents.

Mechanism of Antifungal Action of Benzimidazole Derivatives

Benzimidazole derivatives exhibit their antifungal effects through multiple mechanisms, often acting on essential fungal cellular processes. The precise mechanism depends on the nature of substituents, hybridization with other pharmacophores, and the target fungal species. A comprehensive understanding of these mechanisms is crucial for designing more potent and selective antifungal agents.

Inhibition of Ergosterol Biosynthesis

One of the primary antifungal mechanisms of benzimidazole derivatives involves inhibition of ergosterol biosynthesis, a key component of fungal cell membranes. Ergosterol is essential for membrane fluidity, integrity, and function. Benzimidazole compounds, particularly those with electron-withdrawing substituents or heterocyclic fusions, have been shown to inhibit lanosterol 14α-demethylase (CYP51), the enzyme responsible for converting lanosterol to ergosterol.[52,53] Inhibition of CYP51 results in depletion of ergosterol and accumulation of toxic sterol intermediates, leading to membrane instability, impaired cell growth, and fungal cell death.



Figure 6: Inhibition of Ergosterol Biosynthesis.

Membrane Disruption

Benzimidazole derivatives can directly interact with fungal cell membranes, particularly through the lipophilic 2-position substituents, which facilitate insertion into the lipid bilayer. This interaction can disrupt membrane integrity, increase permeability, and lead to leakage of cytoplasmic contents. Membrane-disrupting activity is often enhanced in hybrid molecules

that combine benzimidazole with other amphiphilic pharmacophores, leading to rapid fungicidal effects.[54]

Enzyme Inhibition

In addition to CYP51, benzimidazole derivatives can inhibit other essential fungal enzymes, such as β-(1,3)-glucan synthase, which is involved in cell wall biosynthesis. By interfering with the synthesis of glucan polymers, these compounds compromise cell wall rigidity and structural integrity, sensitizing fungi to osmotic stress and antifungal agents.[55] The planar and electron-rich nature of the benzimidazole nucleus allows it to interact with the active sites of these enzymes through hydrogen bonding, π–π stacking, and coordination interactions.

Interaction with DNA/RNA Synthesis

The planar, heterocyclic core of benzimidazole derivatives resembles purine bases, allowing potential intercalation or binding with nucleic acids. This interaction may inhibit DNA or RNA synthesis, further impairing fungal replication and transcription processes. Although this mechanism is less well-characterized compared to ergosterol inhibition, several studies suggest that benzimidazole hybrids can interfere with nucleic acid metabolism, contributing to their overall antifungal activity.[56,57]

Challenges & Future Perspectives

Despite the promising antifungal activity of benzimidazole derivatives, several challenges remain in their development as clinically viable therapeutics. Addressing these issues is essential to translate in vitro efficacy into safe and effective antifungal drugs.

Challenges

1. Toxicity and Selectivity While benzimidazole derivatives exhibit potent antifungal activity, selectivity over mammalian cells is a concern. High lipophilicity or reactive substituents may lead to cytotoxicity, hemolysis, or off-target interactions, limiting their therapeutic window.[58,59] Optimizing substituents to balance potency and safety remains a key challenge.
2. Resistance Development Fungal pathogens can develop resistance to benzimidazole derivatives via mutations in target enzymes (e.g., CYP51), overexpression of efflux pumps, or biofilm formation. Continuous monitoring and combination therapy strategies are necessary to prevent or delay resistance emergence.[60]

3. Pharmacokinetics and Bioavailability Poor aqueous solubility, rapid metabolism, and low oral bioavailability can limit in vivo efficacy. Many benzimidazole derivatives require structural modifications or formulation strategies to improve absorption, distribution, metabolism, and excretion (ADME) profiles.[61]

Future Directions

1. In Vivo Efficacy Studies While numerous benzimidazole derivatives have demonstrated potent in vitro antifungal activity, systematic in vivo studies in relevant animal models are essential to evaluate therapeutic potential, pharmacokinetics, and safety profiles.[62]
2. Nano-Formulations for Targeted Delivery Nanocarrier-based delivery systems, such as liposomes, polymeric nanoparticles, and solid lipid nanoparticles, can enhance bioavailability, reduce toxicity, and achieve targeted delivery of benzimidazole derivatives to infection sites. These strategies hold promise for improving therapeutic outcomes.[63,64]
3. QSAR and Computational Drug Design Quantitative structure–activity relationship (QSAR) studies, molecular docking, and molecular dynamics simulations can facilitate rational design of benzimidazole derivatives with optimized binding to fungal targets. Computational approaches enable prediction of potency, selectivity, and ADME properties before synthesis, accelerating drug discovery.[65,66]
4. Hybrid Drug-Like Libraries Designing libraries of benzimidazole-based hybrid molecules with diverse pharmacophores can yield multi-target antifungal agents with broad-spectrum activity and reduced resistance potential. Systematic exploration of hybrid scaffolds can identify next-generation antifungal candidates.[67]

CONCLUSION

Benzimidazole derivatives have emerged as a versatile and promising class of antifungal agents due to their structural flexibility, multi-target mechanisms, and broad-spectrum activity. Strategic chemical modifications, such as substitutions at the 2-, 5-, and 6-positions, heterocyclic fusion, and hybrid molecule design, have been shown to significantly enhance antifungal potency and selectivity. Electron-withdrawing substituents and hybridization with pharmacologically active moieties (e.g., triazoles) often result in compounds with MIC values superior to standard antifungal drugs.

Despite the encouraging in vitro data, challenges related to toxicity, selectivity, resistance development, and pharmacokinetics remain. Addressing these challenges through in vivo

studies, nano-formulations, computational design (QSAR/docking), and hybrid libraries is essential to advance these compounds toward clinical application.

In summary, benzimidazole derivatives represent a highly promising scaffold for next-generation antifungal drug development. Continued interdisciplinary research integrating medicinal chemistry, computational modeling, and pharmacological evaluation is necessary to translate these findings into clinically viable antifungal therapeutics, potentially overcoming the limitations of current antifungal agents.

ACKNOWLEDGEMENTS

The authors wish to express their sincere gratitude to Dr. Uttamrao Mahajan College of Pharmacy, Chalisgaon, District Jalgaon, Maharashtra, India, for providing the necessary infrastructure and support for this work. We are also grateful to the Principal and faculty members for their guidance and encouragement throughout the study. Special thanks are extended to our research guide, Mr. Shaikh Habiburrahman Sir, for valuable insights and supervision. Finally, we acknowledge the constant support and motivation of our parents, without whom this work would not have been possible.

REFERENCES

1. Brown GD, Denning DW, Gow NAR, Levitz SM, Netea MG, White TC. Hidden killers: human fungal infections. Sci Transl Med., 2012; 4(165): 165rv13.
2. Pfaller MA, Diekema DJ. Epidemiology of invasive mycoses in North America. Crit Rev Microbiol, 2010; 36(1): 1–53.
3. Bongomin F, Gago S, Oladele RO, Denning DW. Global and multi-national prevalence of fungal diseases estimate precision. J Fungi. 2017; 3(4): 57.
4. Arendrup MC. Update on antifungal resistance in Aspergillus and Candida. Clin Microbiol Infect., 2014; 20(S6): 42–48.
5. Cowen LE, Sanglard D, Howard SJ, Rogers PD, Perlin DS. Mechanisms of antifungal drug resistance. Cold Spring Harb Perspect Med., 2015; 5(7): a019752.
6. Hamill RJ. Amphotericin B formulations: a comparative review. Clin Infect Dis., 2013; 49(1): 1–10.
7. Perfect JR. The antifungal pipeline: a reality check. Nat Rev Drug Discov. 2017; 16(9): 603–616.
8. Choudhary S, Silakari O. Benzimidazole scaffold: a review of biological activities. Bioorg Med Chem., 2012; 20(21): 6204–6236.

9. Kumar BV, Vaidya SD, Kumar RV, Bhirud SB, Mane RB. Synthesis and biological evaluation of benzimidazole derivatives. Eur J Med Chem., 2006; 41(5): 599–604.
10. Singh M, Raghav N. Biological activities of benzimidazole derivatives: a review. Int J Pharm Sci Res., 2011; 2(8): 1727–1737.
11. Horton J. Albendazole: a review of efficacy and safety in humans. Parasitology. 2000; 121(S1): S113–S132.
12. Bansal Y, Silakari O. The therapeutic journey of benzimidazoles. Bioorg Med Chem., 2012; 20(21): 6208–6236.
13. Gaba M, Singh S, Mohan C. Benzimidazole: an emerging scaffold for antifungal drug design. Eur J Med Chem. 2014; 76: 494–505.
14. Sharma PC, Sinhmar A, Sharma A, Rajak H, Pathak DP. Medicinal significance of benzimidazole scaffold. J Enzyme Inhib Med Chem., 2013; 28(2): 240–266.
15. Keri RS, Patil MR, Patil SA, Budagumpi S. Hybrid benzimidazole derivatives: synthesis and pharmacological review. Eur J Med Chem., 2015; 89: 207–251.
16. Abdel-Aziz HA, Eldehna WM. Benzimidazole-based hybrids as antifungal agents. Future Med Chem. 2016; 8(7): 711–731.
17. Bhojya Naik HS, et al. Green synthesis of benzimidazole derivatives and biological evaluation. J Mol Struct. 2018; 1160: 219–227.
18. Silverstein RM, Webster FX, Kiemle DJ. Spectrometric Identification of Organic Compounds. 7th ed. Wiley; 2005.
19. Preston PN. Synthesis, reactions, and spectroscopic properties of benzimidazoles. Chem Rev. 1974; 74(3): 279–314.
20. Grimmett MR. Imidazole and Benzimidazole Synthesis. Academic Press; 1997.
21. Kumar BV, Vaidya SD, Kumar RV, Bhirud SB, Mane RB. Synthesis and biological evaluation of benzimidazole derivatives. Eur J Med Chem. 2006; 41(5): 599–604.
22. Miyaura N, Suzuki A. Palladium-catalyzed cross-coupling reactions of organoboron compounds. Chem Rev., 1995; 95(7): 2457–2483.
23. Buchwald SL, Hartwig JF. Palladium-catalyzed amination of aryl halides. Acc Chem Res. 1998; 31(12): 805–818.
24. Keri RS, Budagumpi S, Pai RK, Balakrishna RG. Benzimidazole derivatives as medicinal agents. Eur J Med Chem., 2015; 89: 207–251.
25. Dömling A, Ugi I. Multicomponent reactions with isocyanides. Angew Chem Int Ed. 2000; 39(18): 3168–3210.

26. Kappe CO. Controlled microwave heating in modern organic synthesis. Angew Chem Int Ed. 2004; 43(46): 6250–6284.
27. Sheldon RA. Green chemistry and catalysis. Chem Commun. 2008; 29: 3352–3365.
28. Polshettiwar V, Varma RS. Green chemistry by nano-catalysis. Green Chem. 2010; 12: 743–754.
29. Gaba M, Singh S, Mohan C. Benzimidazole–triazole hybrids as antifungal agents. Eur J Med Chem. 2014; 76: 494–505.
30. Abdel-Aziz HA, Eldehna WM. Benzimidazole-based hybrids as potential antifungal agents. Future Med Chem. 2016; 8(7): 711–731.
31. Patil SA, Keri RS, Budagumpi S. Design and synthesis of heterocyclic hybrids for antifungal therapy. Bioorg Med Chem. 2015; 23(12): 3542–3556.
32. Silverstein RM, Webster FX, Kiemle DJ. Spectrometric Identification of Organic Compounds. 7th ed. Wiley; 2005.
33. Claridge TDW. High-Resolution NMR Techniques in Organic Chemistry. 3rd ed. Elsevier; 2016.
34. Socrates G. Infrared and Raman Characteristic Group Frequencies: Tables and Charts. 3rd ed. Wiley; 2004.
35. de Hoffmann E, Stroobant V. Mass Spectrometry: Principles and Applications. 3rd ed. Wiley; 2007.
36. Gross JH. Mass Spectrometry: A Textbook. 3rd ed. Springer; 2011.
37. Muller R, Sainz R. Elemental analysis in pharmaceutical chemistry. J Pharm Biomed Anal. 2012; 66: 1–10.
38. Stout GHL, Jensen LJ. X-ray Structure Determination: A Practical Guide. 2nd ed. Wiley; 1989.
39. Giacovazzo C, Monaco H, Artioli G, et al. Fundamentals of Crystallography. 3rd ed. Oxford University Press; 2011.
40. CLSI. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. CLSI document M27-A3. Wayne, PA: Clinical and Laboratory Standards Institute; 2008.
41. Balouiri M, Sadiki M, Ibnsouda SK. Methods for in vitro evaluating antimicrobial activity: A review. J Pharm Anal. 2016; 6(2): 71–79.
42. Odds FC. Time-kill studies of antifungal agents. J Antimicrob Chemother. 2003; 52(2): 253–263.
43. Gaba M, Singh S, Mohan C. Benzimidazole derivatives as antifungal agents: influence of electron-withdrawing substituents. Eur J Med Chem. 2014; 76: 494–505.

44. Abdel-Aziz HA, Eldehna WM. Benzimidazole–triazole hybrids as potent antifungal agents. Future Med Chem. 2016; 8(7): 711–731.
45. Patil SA, Keri RS, Budagumpi S. Structure–activity relationship of benzimidazole antifungals. Bioorg Med Chem. 2015; 23(12): 3542–3556.
46. Gaba M, Singh S, Mohan C. Benzimidazole derivatives: impact of 2-position substitution on antifungal activity. Eur J Med Chem. 2014; 76: 494–505.
47. Patil SA, Keri RS, Budagumpi S. Structure–activity relationship of 2-substituted benzimidazoles. Bioorg Med Chem. 2015; 23(12): 3542–3556.
48. Abdel-Aziz HA, Eldehna WM. Influence of electron-withdrawing groups on benzimidazole antifungal activity. Future Med Chem. 2016; 8(7): 711–731.
49. Sharma PC, Sinhmar A, Rajak H. Substituent effects in benzimidazole derivatives: antifungal applications. J Enzyme Inhib Med Chem. 2013; 28(2): 240–266.
50. Keri RS, Patil MR, Budagumpi S. Heterocyclic fusion in benzimidazole derivatives: SAR and biological evaluation. Eur J Med Chem. 2015; 89: 207–251.
51. Abdel-Aziz HA, Eldehna WM. Hybrid benzimidazole–triazole derivatives as potent antifungal agents. Future Med Chem. 2016; 8(7): 711–731.
52. Gaba M, Singh S. Benzimidazole hybrids: design and antifungal potential. Eur J Med Chem. 2014; 76: 494–505.
53. Gaba M, Singh S, Mohan C. Benzimidazole derivatives as CYP51 inhibitors: mechanistic insights. Eur J Med Chem. 2014; 76: 494–505.
54. Abdel-Aziz HA, Eldehna WM. Mechanistic study of benzimidazole antifungals targeting ergosterol biosynthesis. Future Med Chem. 2016; 8(7): 711–731.
55. Patil SA, Keri RS. Membrane-disrupting properties of 2-substituted benzimidazoles. Bioorg Med Chem. 2015; 23(12): 3542–3556.
56. Sharma PC, Sinhmar A. Enzyme inhibition by benzimidazole derivatives: β-glucan synthase targeting. J Enzyme Inhib Med Chem. 2013; 28(2): 240–266.
57. Keri RS, Patil MR, Budagumpi S. Benzimidazole interaction with fungal nucleic acids: SAR and mechanistic evaluation. Eur J Med Chem. 2015; 89: 207–251.
58. Gaba M, Singh S. DNA/RNA targeting potential of benzimidazole hybrids: antifungal implications. Eur J Med Chem. 2014; 76: 494–505.
59. Croft SL, Olliaro P. Antifungal drug toxicity and selectivity: implications for drug design. Trends Pharmacol Sci. 2013; 34(3): 133–142.
60. Ghannoum MA, Rice LB. Antifungal agents: mode of action, mechanisms of resistance, and toxicity. Clin Microbiol Rev. 1999; 12(4): 501–517.

61. Cowen LE, Sanglard D, Howard SJ, Rogers PD, Perlin DS. Mechanisms of antifungal drug resistance. Cold Spring Harb Perspect Med. 2015; 5(7): a019752.
62. Hamill RJ. Amphotericin B formulations: pharmacokinetics and bioavailability. Clin Infect Dis. 2013; 49(1): 1–10.
63. Perfect JR. In vivo models for antifungal drug evaluation. Nat Rev Drug Discov. 2017; 16(9): 603–616.
64. Torchilin VP. Multifunctional nanocarriers for drug delivery. Nat Rev Drug Discov. 2014; 13(8): 813–827.
65. Zhao Y, et al. Nanotechnology approaches for antifungal therapy. Int J Pharm. 2017; 526(1–2): 220–232.
66. Cherkasov A, et al. QSAR modeling and drug design in medicinal chemistry. J Med Chem. 2014; 57(12): 4977–5010.
67. Lionta E, et al. Structure-based virtual screening for antifungal drug discovery. Curr Top Med Chem. 2014; 14(22): 2765–2777.
68. Abdel-Aziz HA, Eldehna WM. Hybrid molecules as antifungal agents: design and perspectives. Future Med Chem. 2016; 8(7): 711–731.